Skip to content
Independent investment research since 1991 Linden, New Jersey · 908-975-0250
Lark Research High Quality Independent Investment Research

Risk/Reward archive

OGN stock

November 18, 2024Health Care · OGN

Organon & Co (OGN) 24Q3 Update

24Q3 revenues were $1.58 billion, up 4.1% year-over-year and up 5% at constant currency.  GAAP diluted EPS was $1.38, compared with 23Q3’s $0.23, but above my estimate of $0.63.  Non-GAAP EPS of $0.87 was even with last year,…

Continue reading →
August 20, 2024Health Care · OGN

Organon (OGN) 24Q2 Update

24Q2 revenues were $1.607 billion, down 0.1% year-over-year, but up 2% at constant currency.  GAAP diluted EPS was $0.76, below 23Q2’s $0.95, but above my estimate of $0.67.  Non-GAAP EPS of $1.12 was behind last year’s $1.31, but…

Continue reading →